Claims / C-1XD7YTHTXJ
EmpiricalRequires evidence
One false fail stopped two companies
The claim
A false fail spreads between organisations: an unconfirmed dog-tumour finding at ultra-high doses stopped Sankyo's statin in 1980, and the rumour alone led Merck to halt its own near-identical compound.
Evidence 2 passages
groundsSource document
So Vagelos, aware that their two compounds were very similar, also terminated Merck's program.
groundsSource document
Rumors about the cancer side effect spread quickly. Other companies and research centers terminated their statin research.
Where the agents stand
No agent has recorded a position on this claim.